JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 46:1258-1263, doi:10.1016/j.jacc.2005.06.058
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maree, A. O.
Right arrow Articles by Fitzgerald, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maree, A. O.
Right arrow Articles by Fitzgerald, D. J.

Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease

Andrew O. Maree, MSc, MD*, Ronan J. Curtin, MSc, MD*, Michelle Dooley, BSc*, Ronan M. Conroy, BA, DSc{dagger}, Peter Crean, MD, FRCPI{ddagger}, Dermot Cox, BSc, PhD*,* and Desmond J. Fitzgerald, MD, FRCPI§

* Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland
{dagger} Department of Epidemiology and Public Health, Royal College of Surgeons in Ireland, Dublin, Ireland
{ddagger} Department of Cardiology, Beaumont Hospital, Dublin, Ireland
§ Department of Cardiology, St. James’s Hospital, Dublin, Ireland



View larger version (19K):

[in a new window]
 
Figure 1 The role of cyclooxygenase-1 in thromboxane (TX) synthesis and the inhibitory action of aspirin. PGH2 = prostaglandin H2.

 


View larger version (16K):

[in a new window]
 
Figure 2 A sigmoid relationship between serum thromboxane (TX) (ng/ml) on the y-axis and platelet TX (ng/ml) (TX generated when exogenous arachidonic acid is added to platelets) on the x-axis is evident (n = 45, R2 = 0.67). The point of inflection of the graph occurs at a serum TX level of 2.2 ng/ml.

 


View larger version (14K):

[in a new window]
 
Figure 3 Platelet thromboxane generation (ng/ml) on the x-axis correlates with arachidonic acid-induced platelet aggregation (%) on the y-axis (n = 45, R2 = 0.9). Both variables depend on cyclooxygenase (COX) activity. Two distinct populations are evident reflecting absence and presence of active platelet COX.

 


View larger version (11K):

[in a new window]
 
Figure 4 The relationship between serum thromboxane (TX) and arachidonic acid-induced platelet aggregation (AA Agg). At thromboxane levels above 2 ng/ml the population divides into two groups, one with full inhibition and the other with no inhibition of arachidonic acid-induced platelet aggregation.

 


View larger version (13K):

[in a new window]
 
Figure 5 Probability of an incomplete response to aspirin (serum thromboxane >2.2 ng/ml) on the y-axis is related to patient weight on the x-axis and stratified by patient age. Weight and age are significant independent predictors of aspirin response on multivariate analysis (p = 0.025 and 0.0086, respectively).

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.